Autres langues Organon & Co.

Actions

OGN

US68622V1061

Marché Fermé - Nyse Autres places de cotation 22:00:02 17/05/2024			Varia. 5j.	Varia. 1 janv.
21,8 ^USD	+1,30 %		+6,76 %	+51,18 %

08/05	Organon annonce la fixation du prix d'une offre de billets de premier rang d'un milliard de dollars	MT
07/05	Organon prévoit des offres de billets de premier rang garantis et non garantis pour un total de 1 milliard de dollars	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Organon & Co and Organon Foreign Debt Co-Issuer B.V Closes Their Previously Announces Private Offering of $500 Million of 6.750% Senior Secured Notes Due 2034 and $500 Million of 7.875% Senior Unsecured Notes Due 2034	17/05
Organon Reports Pricing of $1 Billion Senior Notes Offering	08/05
Organon Announces Pricing of $1.0 Billion Senior Notes Offering	08/05
Organon & Co. and Organon Foreign Debt Co-Issuer B.V. Announces Pricing of $1.0 Billion Senior Notes Offering	08/05
Organon Plans Offerings of Secured, Unsecured Senior Notes Totaling $1 Billion	07/05
Organon Announces Proposed $1.0 Billion Senior Notes Offering	07/05
Organon & Co. and Organon Foreign Debt Co-Issuer BV Announces Proposed $1.0 Billion Senior Notes Offering	07/05
Organon : Q1 2024 Transcript	03/05
Organon's Q1 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance, Quarterly Dividend Maintained	02/05
Organon : Q1 2024 Earnings Presentation	02/05
Organon : 2024 Annual Meeting of Shareholders	02/05
Earnings Flash (OGN) ORGANON & CO. Reports Q1 Revenue $1.62B, vs. Street Est of $1.56B	02/05
Organon: Q1 Earnings Snapshot	02/05
Earnings Flash (OGN) ORGANON & CO. Reports Q1 EPS $1.22, vs. Street Est of $0.93	02/05
Organon Reports Results for the First Quarter Ended March 31, 2024	02/05
Organon & Co. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Organon & Co. Provides Earnings Guidance for the Year 2023	02/05
Organon & Co Declares Quarterly Dividend on Common Stock, Payable on June 13, 2024	02/05
El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios	08/04
Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte	08/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Organon & Co.

Actions

OGN

US68622V1061

Autres langues

Filtres